Lilly & Lime: The Swimsuit Solution For Women With A D Cup And Up

Eli Lilly and Company LLY announced that it has inked a development deal with DexCom, Inc. DXCM  to integrate the latter’s continuous glucose monitoring (CGM) products and tools into Lilly’s Connected Diabetes Ecosystem.

Quotes in the article

> Eli Lilly and Co


▲ 83.60
+0.12 +0.14% DXCM

▼ 54.96
-0.18 -0.33% SCMP

▲ 10.43
+0.03 +0.24% LGND

▲ 131.41
+1.45 +1.12%

A Connected Diabetes Ecosystem connects devices and technologies to provide solutions that can cater to an individual’s unique needs in managing diabetes.  In fact, devices such as CGM, smart-pens and insulin pumps, drugs, apps and other analytical tools can link patients and their care teams to deal with the disease in a better way. The Connected Diabetes Ecosystem will depend on Lilly’s core diabetes expertise along with the devices and tools provided by Dexcom.

Per Lilly, the agreement with Dexcom will enable the company to reduce the daily burden for people with diabetes. Studies are expected to begin by the end of 2017.

So far this year, shares of Lilly have increased 13.5% compared with the industry’s gain of 14.8%.

a close up of a map© Provided by Zacks-FinanceENUS

Lilly has a strong portfolio of diabetes treatments including Trulicity (GLP-1), Jardiance (SGLT-2), Trajenta, Humulin, Basaglar, Humalog, and Glyxambi. Also, it has a diabetes alliance with Boehringer Ingelheim for many of these products. The company is seeking label expansion of some of these drugs.

Zacks Rank & Stocks to Consider

Lilly carries a Zacks Rank #3 (Hold). Some better-ranked health care stocks in the same space are Sucampo Pharmaceuticals SCMP and Ligand Pharmaceuticals LGND carrying a Zacks Rank #2 (Buy). You can see

the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Sucampo’s earnings per share estimates have moved up from $1.01 to $1.12 for 2017 and from $1.06 to $1.19 for 2018 over the last 30 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 15.63%.

Ligand’s earnings per share estimates have climbed $3.68 to $3.70 for 2018 over the last 60 days. The company pulled off a positive earnings surprise in two of the trailing four quarters, with an average beat of 8.22%. The share price of the company has increased 27.9% year to date.

Wall Street’s Next Amazon

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>

Source :

Lilly Inks Deal to Include Dexcom Products in Diabetes System
Eli Lilly Bets Big on Insulin-Delivery Devices
Eli Lilly Quietly Works on Wearable Devices in Lab Established in 2015
The Price Of Insulin At Eli Lilly More Than Tripled Under The Guidance Of Trump’s HHS Pick, Alex Azar
Lilly Pulitzer Brand Features Hamilton Princess
DexCom teams up with Lilly to combine CGM into insulin lineup
HHS nominee Azar made millions working for drugmaker Lilly
Lilly Singh 360 Video Confessional
Global Premature Ejaculation Treatment Market 2017-2021 - Key vendors are Absorption Pharmaceuticals, Bayer, Eli Lilly & Regent Pacific Group - Research and Markets
Miss Lilly's angels 'Come Together' for community picnic
[LIMITED STOCK!] Related eBay Products